Related Experiment Videos
[Chemotherapy in advanced sarcomas (author's transl)]
Deutsche Medizinische Wochenschrift (1946)
|September 11, 1981
Summary
A new chemotherapy combination of ifosfamide and cis-platinum shows promise for treating metastasizing sarcomas, even after prior treatments. This combination offers a viable alternative for bone and soft tissue sarcomas when standard therapies fail.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Metastatic sarcomas pose a significant treatment challenge.
- Existing chemotherapy regimens, including CYVADIC, have limitations, especially in pretreated patients.
Purpose of the Study:
- To evaluate the efficacy of two chemotherapy combinations in patients with metastasizing sarcomas.
- To assess if ifosfamide and cis-platinum is a viable alternative, particularly in patients previously treated with adriamycin-containing regimens.
Main Methods:
- A total of 43 patients with metastasizing sarcomas were enrolled.
- Patients received either vincristine, adriamycin, and cis-platinum (n=21) or ifosfamide and cis-platinum (n=22) every three weeks.
Main Results:
- Objective tumor regression was observed in 10 patients treated with vincristine, adriamycin, and cis-platinum.
- Nine patients responded to the ifosfamide and cis-platinum combination, a notable outcome given that 16 had prior adriamycin exposure.
- The ifosfamide and cis-platinum combination demonstrated significant efficacy, even in heavily pretreated patients.
Conclusions:
- The combination of ifosfamide and cis-platinum is a promising treatment for metastatic bone and soft tissue sarcomas.
- This regimen offers a valuable alternative when standard treatments like CYVADIC are unsuccessful or have been previously administered.